First Tracks Biotherapeutics Inc TRAX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
First Tracks Biotherapeutics Announces Participation in Upcoming Investor Conferences
First Tracks Biotherapeutics Announces $200 Million Private Placement
First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
First Tracks Biotherapeutics Announces Participation in September Investor Conferences
First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Trading Information
- Previous Close Price
- $49.04
- Day Range
- $44.47–49.10
- 52-Week Range
- $14.72–50.17
- Bid/Ask
- $44.00 / $45.55
- Shares Outstanding
- 42.02M
- Market Cap
- $1.91B
- Volume/Avg
- 571,288 / 827,283
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- —
Valuation
Metric | TRAX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 10.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | TRAX |
|---|---|
Quick Ratio | 8.76 |
Current Ratio | 9.16 |
Interest Coverage | — |
Quick Ratio
TRAX
Profitability
Metric | TRAX |
|---|---|
Return on Assets (Normalized) | −30.90% |
Return on Equity (Normalized) | −34.16% |
Return on Invested Capital (Normalized) | −36.94% |
Return on Assets
TRAX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|y<nDsh | LOCK|>#dG | $138B | |||
| Moderna Inc MRNA | LOCK|S?tD#> | LOCK|^> | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|yw<GdS | LOCK|rzjr | $93B | |||
| argenx SE ADR ARGX | LOCK|$bj>&! | LOCK|y$# | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|^shVB< | LOCK|w!W | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|Bxr!VfPR | LOCK|%$^R | $30B | |||
| Incyte Corp INCY | LOCK|l>SWc^! | LOCK|lY | $24B | |||
| BioNTech SE ADR BNTX | LOCK|m>&d#! | LOCK|Hk< | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|$N@<m$ | LOCK|d@&r | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|<f<r>^ | LOCK|#L | $15B |
United States